A comparison of invasive and cytotoxic Pseudomonas aeruginosa strain-induced corneal disease responses to therapeutics

Current Eye Research

Volumn 27, Issue 5, 2003, Pages 289-299

  Lee, Ellen J ^a   Truong, Tan N ^a   Mendoza, Myra N ^a   Fleiszig, Suzanne M J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibiotics; Keratitis; Mouse; Pseudomonas aeruginosa; Steroids

Indexed keywords

EYE DROPS; OFLOXACIN; PREDNISOLONE ACETATE; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; KERATITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; CORNEA; CORNEAL ULCER; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; FEMALE; GLUCOCORTICOIDS; MICE; MICE, INBRED C57BL; OFLOXACIN; PREDNISOLONE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 0345275986     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.27.5.289.17220     Document Type: Article

References (45)

1. Laibson PR. Cornea and sciera. Arch Ophthalmol. 1972;88:553-574.
2. Fleiszig SMJ, Zaidi TS, Preston MJ, Grout M, Evans DJ, Pier GB. Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa. Infect Immun. 1996;64:2288-2294.
3. Fleiszig SMJ, Wiener-Kronish JP, Miyazaki H, Vallas V, Mostov KE, Kanda D, Sawa T, Yen TSB, Frank DW. Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infect Immun. 1997;65:579-586.
4. Fleiszig SMJ, Zaidi TS, Fletcher EL, Preston MJ, Pier GB. Pseudomonas aeruginosa invades corneal epithelial cells during experimental infection. Infect Immun. 1994;62:3485-3493.
5. Fleiszig SMJ, Zaidi TS, Pier GB. Pseudomonas aeruginosa invasion of and multiplication within corneal epithelial cells in vitro. Infect Immun. 1995;63:4072-4077.
6. Apodaca G, Bomsel M, Lindstedt R, Engel J, Frank D, Mostov KE, Wiener-Kronish J. Characterization of Pseudomonas aeruginosa-induced MDCK cell injury: Glycosylation-defective host cells are resistant to bacterial killing. Infect Immun. 1995;63:1541-1551.
7. Hauser AR, Engel JN Pseudomonas aeruginosa induces Type-III-secretion- mediated apoptosis of macrophages and epithelial cells. Infect Immun. 1999;67:5530-5537.
8. Dacheux D, Attree I, Schneider C, Toussaint B. Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system. Infect Immun. 1999;67:6164-6167.
9. Evans DJ, Frank DW, Finck-Barbançon V, Wu C, Fleiszig SMJ. Pseudomonas aeruginosa invasion and cytotoxicity are independent events, both of which involve protein tyrosine kinase activity. Infect Immun. 1998;66:1453-1459.
10. Cowell BA, Weissman BA, Yeung KK, Johnson L, Ho S, Van R, Bruckner D, Mondino B, Fleiszig SMJ. Phenotype of Pseudomonas aeruginosa isolates causing corneal infection between 1997 and 2000. Cornea. [In press] 2003.
11. Cole N, Willcox MDP, Fleiszig SMJ, Stapleton F, Bao B, Tout S, Husband A. Different strains of Pseudomonas aeruginosa isolated from ocular infections or inflammation display distinct corneal pathologies in an animal model. Curr Eye Res. 1998;17:730-735.
12. Baum J, Barza M. The evolution of antibiotic therapy for bacterial conjunctivitis and keratitis: 1970-2000. Cornea. 2000;19:659-672.
13. Khokhar S, Sindhu N, Mirdha BR. Comparison of topical 0.3% ofloxacin to fortified tobramycin-cefazolin in the therapy of bacterial keratitis. Infection. 2000;28:149-152.
14. Hyndiuk RA, Eiferman RA, Caldwell DR, Rosenwasser GO, Santos CI, Katz HR, Badrinath SS, Reddy MK, Adenis JP, Klauss V. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers: Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996;103:1854-1862.
15. O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P, and the Bacterial Keratitis Study Research Group. Efficacy of ofloxacin vs. cefazolin and tobramycin in the therapy for bacterial keratitis: Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995;113:1257-1265.
16. Panda A, Ahuja R, Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis. Eye. 1999;13:744-747.
17. Parks DJ, Abrams DA, Sarfarazi FA, Katz HR. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol. 1993;115:471-477.
18. Guzek JP, Chacko D, Kettering JD, Wessels IF, Aprecio RM. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis. Cornea. 1994;13:500-504.
19. Gritz DC, McDonnell PJ, Lee TY, Tang-Liu D, Hubbard BB, Gwon A. Topical ofloxacin in the treatment of Pseudomonas aeruginosa keratitis in a rabbit model. Cornea. 1992;11:143-147.
20. Steuhl K-P, Döring G, Henni A, Thiel H, Botzenhart K. Relevance of host-derived and bacterial factors in Pseudomonas aeruginosa corneal infections. Invest Ophthalmol Vis Sci. 1987;28:1559-1568.
21. Hobden JA, Engel LS, Callegan MC, Hill JM, Gebhardt BM, O'Callaghan RJ. Pseudomonas aeruginosa keratitis in leukopenic rabbits. Curr Eye Res. 1993;12:461-467.
22. Twining SS, Lohr KM, Moulder JE. The immune system in experimental Pseudomonas keratitis: Model and early effects. Invest Ophthalmol Vis Sci. 1986;27:507-515.
23. Kessler E, Mondino BJ, Brown SI. The corneal response to Pseudomonas aeruginosa: Histopathological and enzymatic characterization. Invest Ophthalmol Vis Sci. 1977;16:116-125.
24. Waterbury L, Kunysz EA, Beuerman R. Effects of steroidal and non-steroidal anti-inflammatory agents on corneal wound healing. J Ocul Pharmacol. 1987;3:43-54.
25. Singh G. Corticosteroids in corneal endothelial wound healing. Ann Ophthalmol. 1985;17:238-243.
26. Phillips K, Arffa R, Cintron C, Rose J, Miller D, Kublin CL, Kenyon KR. Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol. 1983;101:640-643.
27. Wilhelmus KR. Indecision about corticosteroids for bacterial keratitis: An evidence-based update. Ophthalmology. 2002;109:835-844.
28. Carimichael TR, Gelfand Y, Welsh NH. Topical steroids in the treatment of central and paracentral corneal ulcers. Br J Ophthalmol. 1990;74:528-531.
29. Wilhelmus KR, Hyndiuk RA, Caldwell DR, Abshire RL, Folkens AT, Godio LB. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis: The Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Arch Ophthalmol. 1993;111:1210-1208.
30. Leibowitz HM, Kupferman A. Topically administered corticosteroids: Effect on antibiotic-treated bacterial keratitis. Arch Ophthalmol. 1980;98:1287-1290.
31. Badenoch PR, Hay GJ, McDonald PJ, Coster DJ. A rat model of bacterial keratitis: Effect of antibiotics and corticosteroid. Arch Ophthalmol. 1985;103:718-722.
32. Bohigian GM, Foster CS. Treatment of Pseudomonas keratitis in the rabbit with antibiotic-steroid combinations. Invest Ophthalmol Vis Sci. 1977;16:553-556.
33. Davis SD, Sarff LD, Hyndiuk RA. Corticosteroid in experimentally induced Pseudomonas keratitis: Failure of prednisolone to impair the efficacy of tobramycin and carbenicillin therapy. Arch Ophthalmol. 1978;96:126-128.
34. Hobden JA, O'Callaghan RJ, Hill JM, Hagenah M, Insler MS, Reidy JJ. Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis. Curr Eye Res. 1992;11:259-266.
35. Hobden JA, Engel LS, Hill JM, Callegan MC, O'Callaghan RJ. Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1993;12:469-473.
36. Hobden JA, Hill JM, Engel LS, O'Callaghan RJ. Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen. Antimicrob Agents Chemother. 1993;37:1856-1859.
37. Engel LS, Callegan MC, Hobden JA, Reidy JJ, Hill JM, O'Callaghan RJ. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1995;14:229-234.
38. Vaudaux P, Waldvogel FA. Gentamicin antibacterial activity in the presence of human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1979;16:743-749.
39. Sansonetti PJ. Rupture, invasion and inflammatory destruction of the intestinal barrier by Shigella, making sense of prokaryote-eukaryote cross-talks. FEMS Microbiol Rev. 2001;25:3-14.
40. Kaiser P, Rothwell L, Galyov EE, Barrow PA, Burnside J, Wigley P. Differential cytokine expression in avian cells in response to invasion by Salmonella typhimurium, Salmonella enteritidis and Salmonella gallinarum. Microbiology. 2000;146:3217-3226.
41. Preston MJ, Fleiszig SMJ, Zaidi TS, Goldberg JB, Shortridge VD, Vasil ML, Pier GB. Rapid and sensitive method for evaluating Pseudomonas aeruginosa virulence factors during corneal infections in mice. Infect Immun. 1995;63:3497-3501.
42. Lee EJ, Mendoza MN, Fleiszig SMJ. The relationship between corneal epithelial integrity and susceptibility to Pseudomonas aeruginosa infection in vivo. Invest Ophthalmol Vis Sci. 2001;42:S253.
43. Beisel KW, Hazlett LD, Berk RS. Dominant susceptibility effect on the murine corneal response to Pseudomonas aeruginosa. Proc Soc Exp Biol Med. 1983;172:488-491.
44. Kernacki KA, Fridman R, Hazlett LD, Lande MA, Berk RS. In vivo characterization of host and bacterial protease expression during Pseudomonas aeruginosa corneal infections in naive and immunized mice. Curr Eye Res. 1997;16:289-297.
45. Kernacki KA, Hobden JA, Hazlett LD, Fridman R, Berk RS. In vivo bacterial protease production during Pseudomonas aeruginosa corneal infection. Invest Ophthalmol Vis Sci. 1995;36:1371-1378.